Amalgamated Bank Acquires 1,926 Shares of Danaher Corporation (NYSE:DHR)

Amalgamated Bank increased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 125,164 shares of the conglomerate's stock after purchasing an additional 1,926 shares during the quarter. Amalgamated Bank's holdings in Danaher were worth $25,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Danaher by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate's stock valued at $13,715,641,000 after purchasing an additional 315,912 shares in the last quarter. Geode Capital Management LLC increased its position in Danaher by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock valued at $3,056,996,000 after acquiring an additional 315,446 shares during the last quarter. Norges Bank purchased a new stake in Danaher during the fourth quarter valued at $2,130,740,000. Northern Trust Corp increased its position in Danaher by 14.3% during the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate's stock valued at $1,821,477,000 after acquiring an additional 992,594 shares during the last quarter. Finally, Capital World Investors increased its position in Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after acquiring an additional 1,566,658 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on DHR. Evercore ISI reduced their price objective on Danaher from $240.00 to $230.00 and set an "outperform" rating for the company in a research report on Tuesday, April 22nd. Royal Bank Of Canada reiterated an "outperform" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Jefferies Financial Group reduced their price objective on Danaher from $260.00 to $230.00 and set a "buy" rating for the company in a research report on Tuesday, April 22nd. TD Cowen upped their price objective on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Finally, JPMorgan Chase & Co. reduced their price objective on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Tuesday, April 22nd. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $248.61.

Danaher Stock Performance

NYSE:DHR opened at $198.20 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $281.70. The stock has a 50-day moving average price of $194.84 and a 200 day moving average price of $208.15. The stock has a market capitalization of $141.84 billion, a P/E ratio of 38.48, a P/E/G ratio of 2.79 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.65%. Danaher's dividend payout ratio is currently 24.85%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.